Advanced age, anti- coagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial brillation. Ann Intern Med. 2004;141(10):745-752. 166. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial brillation. N Engl J Med. 2003;349(11):1019-1026. 167. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagula- tion for patients with nonrheumatic atrial brillation. N Engl J Med. 1996;335(8):540-546. 168. Walker AM, Bennett D. Epidemiology and outcomes in patients with atrial brillation in the United States. Heart Rhythm. 2008;5(10):1365-1372. 169. Singer DE, Chang Y, Fang MC, et al. Should patient char- acteristics in uence target anticoagulation intensity for stroke prevention in nonvalvular atrial brillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes. 2009;2(4): 297-304. 170. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial brillation in community-based practise. J Thromb Haemost. 2008;6(10):1647-1654. 171. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical prac- tice guidelines. Chest. 2012;141(2)(suppl):e44S-e88S. 172. Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial brillation: a record linkage study in a large British population. Heart. 2005;91(4):472-477. 173. White HD, Gruber M, Feyzi J, et al. Comparison of out- comes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239-245. 174. Connolly SJ, Pogue J, Eikelboom J, et al; ACTIVE W Investigators. 